Skip to main content
  • Register
  • Help
  • Contact us

Terns Pharmaceuticals Inc (TERN) USD0.0001

Sell:$17.21 Buy:$18.04 Change: $0.75 (4.47%)
Prices delayed by at least 15 minutes | Switch to live prices |
Sell:$17.21
Buy:$18.04
Change: $0.75 (4.47%)
Prices delayed by at least 15 minutes | Switch to live prices |
Sell:$17.21
Buy:$18.04
Change: $0.75 (4.47%)
Prices delayed by at least 15 minutes | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Terns Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and other chronic liver diseases. The Company’s NASH pipeline includes multiple single-agent and combination therapy candidates that provide opportunities to address the multifaceted nature of NASH and provide clinical benefits for patients. The Company’s TERN-101 is a liver-distributed, non-bile acid Farnesoid X Receptor (FXR) that has demonstrated a profile and improved target engagement due to its sustained FXR activation in the liver but only transient FXR activation in the intestine. Its TERN-101 is in a Phase 2a clinical trial. Its TERN-201 is an inhibitor of vascular adhesion protein-1 (VAP-1) that has demonstrated target engagement in clinical trials. The TERN-201 is in Phase 1b clinical trial. Its TERN-501 is in Phase 1a clinical trial.

Contact details

Address:
1065 East Hillsdale Blvd.
Suite 100, Suite 100
FOSTER CITY
94404
United States
Telephone:
+1 (650) 5255535
Website:
https://ternspharma.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
TERN
ISIN:
US8808811074
Market cap:
$429.64 million
Shares in issue:
25.13 million
Sector:
Pharmaceuticals
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
n/a

Key personnel


Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.